Oasmia Competitors

Summary

OASMYDelisted Stock

USD 0.06 0.00 0.00%

Oasmia Pharmaceutical competes with Volaris, Delta Air, Copa Holdings, Victorias Secret, and Canada Goose; as well as few others. The company classifies itself under Healthcare sector and is part of Drug Manufacturers—Specialty & Generic industry. Analyzing Oasmia Pharmaceutical competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Oasmia Pharmaceutical to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.

You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of Oasmia Pharmaceutical competition on your existing holdings.

Specify up to 10 symbols:

Hype

Prediction

Low	Estimated	High
0.06	0.06	0.06

Details

Intrinsic

Valuation

Low	Real	High
0.06	0.06	0.06

Details

Oasmia Pharmaceutical Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Oasmia Pharmaceutical and its competitors represents the degree of relationship between the price movements of corresponding pink sheets. A correlation of about +1.0 implies that the price of Oasmia and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Oasmia Pharmaceutical does not affect the price movement of the other competitor.

	VLRS	DAL	CPA	VSCO	GOOS	ALK	GAP
VLRS		0.91	0.06	0.93	-0.82	0.91	0.72	VLRS
DAL	0.91		0.24	0.85	-0.77	0.86	0.71	DAL
CPA	0.06	0.24		-0.19	-0.13	-0.07	-0.3	CPA
VSCO	0.93	0.85	-0.19		-0.69	0.94	0.86	VSCO
GOOS	-0.82	-0.77	-0.13	-0.69		-0.62	-0.47	GOOS
ALK	0.91	0.86	-0.07	0.94	-0.62		0.77	ALK
GAP	0.72	0.71	-0.3	0.86	-0.47	0.77		GAP
	VLRS	DAL	CPA	VSCO	GOOS	ALK	GAP

Click cells to compare fundamentals

Check Volatility

Backtest Portfolio

High positive correlations

ALK	+ 0.94	VSCO
VSCO	+ 0.93	VLRS
DAL	+ 0.91	VLRS
ALK	+ 0.91	VLRS
ALK	+ 0.86	DAL
GAP	+ 0.86	VSCO

High negative correlations

GOOS	- 0.82	VLRS
GOOS	- 0.77	DAL
GOOS	- 0.69	VSCO
ALK	- 0.62	GOOS
GAP	- 0.47	GOOS
GAP	- 0.3	CPA

Risk-Adjusted Indicators

There is a big difference between Oasmia Pink Sheet performing well and Oasmia Pharmaceutical Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Oasmia Pharmaceutical's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.

	Mean Deviation	Jensen Alpha	Sortino Ratio	Treynor Ratio	Semi Deviation	Expected Shortfall	Potential Upside	Value @Risk	Maximum Drawdown
VLRS	1.60	0.42	0.17	(1.79)	1.51	(1.77)	4.46	(2.63)	9.30
DAL	1.73	0.35	0.23	0.28	1.34	(2.09)	4.11	(2.91)	10.43
CPA	1.45	(0.04)	(0.03)	(0.01)	2.68	(1.42)	3.72	(2.73)	17.31
VSCO	2.36	1.00	0.43	1.60	1.64	(2.92)	6.62	(3.13)	13.33
GOOS	1.90	(0.07)	0.00	(0.20)	0.00	0.00	4.31	(4.19)	16.44
ALK	1.77	0.59	0.37	0.77	1.05	(2.17)	4.57	(2.76)	14.50
GAP	1.86	0.18	0.10	0.22	1.80	(2.25)	5.26	(3.38)	16.96

Unable to evaluate fundamental data of [VLRS, DAL, CPA, VSCO, GOOS, ALK, GAP] at this time. Please try again later

All Fundamental Data

Oasmia Pharmaceutical Competitive Analysis

The better you understand Oasmia Pharmaceutical competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Oasmia Pharmaceutical's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Oasmia Pharmaceutical's competition over several years is one of the best ways to analyze its investment potential.

Better Than Average

Worse Than Peers

View Performance Chart

	OASMY	VLRS	DAL	CPA	VSCO	GOOS	ALK	GAP
	0.00 0.06 Oasmia	0.71 8.35 Volaris	0.08 61.00 Delta	0.72 86.78 Copa	0.50 45.66 Victorias	2.10 10.22 Canada	0.21 63.27 Alaska	0.48 24.72 Gap,
Market Volatility (90 Days Market Risk)	Very steady	Not too volatile	Very steady	Very steady	Very steady	Not too volatile	Very steady	Very steady
Market Performance (90 Days Performance)	Very Weak	Good	Good	Very Weak	Solid	Very Weak	Solid	OK
Odds of Financial Distress (Probability Of Bankruptcy)	Dangerous	Below Average	Below Average	Below Average	Below Average	Very Low	Low	Very Small
Current Valuation (Equity Enterprise Value)	Over Valued	Under Valued	Fairly Valued	Under Valued	Over Valued	Under Valued	Over Valued	Fairly Valued
Buy or Sell Advice (Average Analysts Consensus)	Not Available	Strong Buy	Strong Buy	Strong Buy	Buy	Hold	Strong Buy	Buy
Trade Advice (90 Days Macroaxis Advice)	Not Rated	Hold	Strong Buy	Hold	Strong Buy	Hold	Strong Buy	Buy
Current Ratio	6.80 X	0.75 X	0.57 X	0.97 X	1.07 X	2.42 X	0.81 X	N/A
Net Asset	594.31 M	5.15 B	73.64 B	5.2 B	4.6 B	1.48 B	15.83 B	11.04 B
Profit Margin	N/A	0.06 %	0.08 %	0.19 %	0.02 %	0.05 %	0.03 %	0.05 %
EBITDA	(97.54 M)	721.02 M	8.78 B	1.08 B	530 M	244.3 M	1.27 B	1.17 B
Current Valuation	6.58 M	3.87 B	59.81 B	4.47 B	6.77 B	1.54 B	11.58 B	11.86 B
Price To Book	0.68 X	3.02 X	2.89 X	1.57 X	8.93 X	3.82 X	1.77 X	2.95 X
Operating Margin	N/A	0.15 %	0.08 %	0.19 %	0.04 %	0.01 %	0.13 %	0.08 %
Retained Earnings	N/A	(148.08 M)	5.65 B	2.1 B	178 M	252.5 M	4.54 B	2.42 B
Current Asset	N/A	7.24 B	9.06 B	907.59 M	N/A	243.04 M	1.66 B	N/A
Five Year Return	N/A	N/A	2.31 %	3.08 %	N/A	N/A	1.95 %	N/A
Beta	0.0522	1.78	1.34	1.47	2.2	1.29	1.59	2.37
Number Of Employees	17	7.2 K	100 K	7.62 K	30 K	4.46 K	23.78 K	85 K
Shares Outstanding	179.35 M	115.1 M	645.28 M	30.65 M	78.62 M	45.8 M	126.94 M	375.07 M
Cash Flow From Operations	(145.56 M)	729.83 M	6.46 B	1.04 B	389 M	164.6 M	1.05 B	1.53 B
Annual Yield	0.12 %	N/A	0.01 %	0.06 %	N/A	N/A	N/A	0.03 %
Total Debt	N/A	3.54 B	27.28 B	1.75 B	2.7 B	728.4 M	3.82 B	5.44 B
Return On Equity	-0.25	0.85	0.41	0.35	0.36	0.2	0.0751	0.3
Return On Asset	-0.0875	0.0534	0.0527	0.0947	0.0345	0.0578	0.0286	0.0566
Number Of Shares Shorted	20.72 K	970.97 K	32.39 M	1.51 M	8.8 M	9.22 M	9.16 M	29.97 M
Book Value Per Share	N/A	0.28 X	21.29 X	50.19 X	5.35 X	3.70 X	35.51 X	7.71 X
Current Liabilities	N/A	7.1 B	17.53 B	985.67 M	N/A	85.9 M	1.8 B	N/A
Total Asset	594.31 M	5.15 B	73.64 B	5.2 B	4.6 B	1.48 B	15.83 B	11.04 B
Debt To Equity	0.01 %	N/A	6.96 %	1.27 %	9.56 %	1.98 %	1.03 %	N/A
Short Ratio	0.03 X	1.00 X	4.00 X	4.79 X	4.30 X	8.87 X	4.57 X	4.35 X
Target Price	6.0	12.3	75.43	146.33	44.7	9.89	73.25	27.69
Last Dividend Paid	N/A	N/A	0.5	N/A	N/A	N/A	N/A	0.6
Shares Owned By Institutions	N/A	63.39 %	80.47 %	94.29 %	93.17 %	82.52 %	88.28 %	64.56 %
Market Capitalization	21.21 M	980.27 M	39.7 B	3.58 B	3.83 B	961.26 M	8.05 B	8.36 B
Price To Earning	N/A	9.29 X	34.29 X	11.20 X	6.18 X	36.57 X	112.95 X	N/A
Price To Earnings To Growth	N/A	1.69 X	39.29 X	0.16 X	(1.72) X	3.02 X	1.30 X	0.91 X
Price To Sales	31.16 X	0.31 X	0.66 X	1.03 X	0.63 X	0.73 X	0.75 X	0.55 X
Net Income	(132.72 M)	7.82 M	4.61 B	514.1 M	109 M	58.4 M	235 M	502 M
Earnings Per Share	N/A	1.66 X	7.16 X	15.11 X	1.96 X	0.41 X	2.54 X	2.02 X
Shares Owned By Insiders	N/A	N/A	0.26 %	N/A	10.77 %	1.56 %	0.44 %	40.96 %
Revenue	26.19 M	3.26 B	58.05 B	3.46 B	6.18 B	1.34 B	10.43 B	14.89 B
Working Capital	N/A	(373 M)	(16.15 B)	(10.51 M)	(81 M)	430.9 M	(1.47 B)	1.3 B
Cash And Equivalents	N/A	750 M	3.27 B	122.42 M	201 M	81.8 M	338 M	N/A
Cash Per Share	N/A	6.43 X	13.11 X	23.65 X	2.47 X	0.78 X	24.83 X	N/A
Gross Profit	(15.25 M)	663 M	9.68 B	1.07 B	2.78 B	733.6 M	2.36 B	6.63 B
Day Typical Price	0.06	8.35	61.0	86.57	45.66	10.15	63.27	24.72
Accumulation Distribution	N/A	N/A	N/A	0.0071	N/A	0.0205	N/A	N/A
Market Facilitation Index	N/A	N/A	N/A	0.62	N/A	0.21	N/A	N/A
Daily Balance Of Power	0.0	(9,223,372,036,855)	(9,223,372,036,855)	1.0	(9,223,372,036,855)	1.0	(9,223,372,036,855)	(9,223,372,036,855)
Period Momentum Indicator	N/A	(0.06)	(0.05)	0.62	(0.23)	0.21	(0.13)	(0.12)
Rate Of Daily Change	1.0	0.99	1.0	1.01	0.99	1.02	1.0	1.0
Day Median Price	0.06	8.35	61.0	86.47	45.66	10.12	63.27	24.72
Price Action Indicator	N/A	(0.03)	(0.03)	0.62	(0.12)	0.21	(0.07)	(0.06)
Coefficient Of Variation	35042.85	507.82	463.27	46971.94	291.78	(7,093)	379.26	960.33
Mean Deviation	5.71	1.6	1.73	1.45	2.36	1.9	1.77	1.86
Jensen Alpha	(0.21)	0.4195	0.3487	(0.04)	1.0	(0.07)	0.5948	0.1822
Total Risk Alpha	(2.43)	0.184	0.2412	(0.25)	0.7303	(0.33)	0.3947	(0.01)
Sortino Ratio	N/A	0.174	0.234	(0.03)	0.4261	N/A	0.3684	0.1012
Downside Variance	N/A	3.54	2.93	7.94	5.28	N/A	2.52	3.96
Standard Deviation	23.84	2.1	2.25	2.3	3.11	2.67	2.54	2.75
Kurtosis	27.06	0.3429	0.8637	12.03	1.49	2.24	8.1	6.03
Potential Upside	N/A	4.46	4.11	3.72	6.62	4.31	4.57	5.26
Treynor Ratio	0.0161	(1.79)	0.2814	(0.01)	1.6	(0.20)	0.7664	0.2208
Maximum Drawdown	190.0	9.3	10.43	17.31	13.33	16.44	14.5	16.96
Variance	568.28	4.39	5.07	5.31	9.64	7.12	6.45	7.57
Market Risk Adjusted Performance	0.0261	(1.78)	0.2914	(0.0006)	1.61	(0.19)	0.7764	0.2308
Risk Adjusted Performance	0.0118	0.1487	0.1627	0.0084	0.2552	(0)	0.1976	0.0826
Skewness	3.63	0.2807	0.806	(2.14)	0.6922	0.6236	1.97	1.72
Semi Deviation	N/A	1.51	1.34	2.68	1.64	N/A	1.05	1.8
Information Ratio	(0.0007)	0.1562	0.178	(0.03)	0.3152	(0.05)	0.2301	0.0731
Value At Risk	(16.67)	(2.63)	(2.91)	(2.73)	(3.13)	(4.19)	(2.76)	(3.38)
Expected Short fall	N/A	(1.77)	(2.09)	(1.42)	(2.92)	N/A	(2.17)	(2.25)
Downside Deviation	N/A	1.88	1.71	2.82	2.3	N/A	1.59	1.99
Semi Variance	N/A	2.29	1.8	7.16	2.68	N/A	1.1	3.24

Oasmia Pharmaceutical Competition Performance Charts

Five steps to successful analysis of Oasmia Pharmaceutical Competition

Oasmia Pharmaceutical's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Oasmia Pharmaceutical in relation to its competition. Oasmia Pharmaceutical's competition analysis typically involves several steps, including:

Identifying the key players in the market: This involves identifying the major competitors of Oasmia Pharmaceutical in the market, both direct and indirect, as well as new entrants and disruptive technologies.
Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Oasmia Pharmaceutical's competitive landscape.
Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Oasmia Pharmaceutical, and developing a strategy to address them.
Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.

Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your Oasmia Pharmaceutical position

In addition to having Oasmia Pharmaceutical in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Gambling Thematic Idea Now

Gambling

Companies that are related to providing gambling services across multiple geographical areas by investing, exploring, or producing software, hardware, and related infrastructure for running gambling operations or trading speculative assets. The Gambling theme has 38 constituents at this time.

You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Gambling Theme or any other thematic opportunities.

View All Next

Launch

Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.

You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.

Other Consideration for investing in Oasmia Pink Sheet

If you are still planning to invest in Oasmia Pharmaceutical check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Oasmia Pharmaceutical's history and understand the potential risks before investing.

	Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
	Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk
	Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
	Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
	Commodity Directory Find actively traded commodities issued by global exchanges
	Technical Analysis Check basic technical indicators and analysis based on most latest market data
	Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios
	Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges
	Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC